The Regulatory Map: Moving Botanical Ingredients Across Markets

For a procurement, regulatory or product owner, the hardest truth about botanical ingredients is that the molecule does not determine the rules — the market, the form and the claim do. An ashwagandha extract sold as a capsule with a structure/function claim in one country, a traditional medicine in another, and an ingredient requiring pre-market authorisation in a third can be chemically identical in all three. Understanding the regulatory map is therefore not a compliance afterthought; it is a sourcing and product-design input that belongs at the start of the project, not the end.

This article sketches that map at a deliberately high level: how the major markets classify botanical ingredients, who the gatekeepers are, and the documentation that travels with a shipment. It is general orientation only. Regulations are detailed, fact-specific and change frequently, so treat everything here as a starting framework to discuss with qualified regulatory counsel and to confirm against the current rules of each destination market.

Why one extract can be four different things

Three variables decide which regulatory box a botanical ingredient falls into, and they interact:

• The claim. A statement about supporting normal function (a structure/function or health claim) generally keeps a product in the food or supplement space. A claim to treat, prevent or cure a disease almost always pushes it into the medicines regime, with a far higher evidence and authorisation burden.
• The history of use. Whether the ingredient has a significant history of consumption as a food — and in which region, and before which cut-off date — can determine whether it is treated as an ordinary food ingredient or as a novel food requiring pre-market authorisation.
• The form and dose. The same plant as a culinary spice, a standardised extract at a concentrated dose, or an isolated constituent can be regulated very differently. Concentration, the part of the plant used and the delivery format all matter.

United States: supplements, foods and the NDI question

In the US, most botanical ingredients reach consumers as dietary supplements, a category created by the Dietary Supplement Health and Education Act of 1994 (DSHEA). DSHEA places dietary supplements under the food umbrella rather than the drug umbrella, which means there is generally no pre-market approval of efficacy. The trade-off is that the responsibility for safety and for truthful labelling sits squarely with the marketer.

New Dietary Ingredient (NDI) notifications

A central concept is the New Dietary Ingredient. Broadly, an ingredient not marketed in the US as a dietary ingredient before the DSHEA cut-off date of 15 October 1994 may be an NDI, and introducing it can require a pre-market NDI notification to the FDA demonstrating a reasonable expectation of safety. There are exceptions — for example, ingredients present in the food supply in a chemically unaltered form. Whether a given extract is 'new', and whether a notification is required, is a fact-specific analysis that turns on the ingredient's marketing history, manufacturing process and conditions of use.

cGMP and labelling

Manufacturing must comply with current Good Manufacturing Practice for dietary supplements under 21 CFR Part 111 (cGMP), which governs identity, purity, strength and composition controls. On claims, the FDA permits structure/function claims (describing an effect on the structure or function of the body) provided they are truthful, not misleading, carry the required disclaimer, and are notified to the FDA within the prescribed window; disease claims are not permitted for supplements. Separately, the Federal Trade Commission (FTC) enforces against deceptive advertising and expects claims to be supported by competent and reliable scientific evidence — a substantiation standard that applies to marketing regardless of the FDA notification.

European Union: food supplements, novel foods and the herbal-medicine route

The EU treats most botanical products as either foods (including food supplements) or medicines, with a structured boundary between them. Food supplements are addressed by the Food Supplements Directive (2002/46/EC), implemented through national law, while the overall food-safety framework and the European Food Safety Authority (EFSA) underpin risk assessment. Health claims are tightly controlled: only claims authorised under the EU health-claims framework may be used, and the bar for authorisation is high.

The Novel Food Regulation

The pivotal question for many extracts is whether they are a novel food. Under Regulation (EU) 2015/2283, a food not used for human consumption to a significant degree within the EU before 15 May 1997 is a novel food and requires pre-market authorisation following an EFSA safety assessment. For botanicals this is consequential: a concentrated extract, a new part of the plant, or a new production process can render an ingredient novel even where the plant itself is familiar. Establishing significant prior consumption history — and its form — is often the determining exercise.

Traditional herbal medicinal products (THMPD)

Where a product is presented for a medicinal purpose, the medicines regime applies. The Traditional Herbal Medicinal Products Directive (2004/24/EC, THMPD) provides a registration route for herbal medicines with a sufficient history of traditional use, lighter than a full marketing authorisation but still requiring quality, safety and traditional-use evidence. Crucially, much of the food-versus-medicine line, and the treatment of specific botanicals, varies between Member States — national variation is the rule, not the exception, so an ingredient cleared in one Member State is not automatically cleared across the bloc.

India: the export side — FSSAI, AYUSH and trade documentation

For an Indian-origin exporter, two domestic frameworks and a layer of trade documentation are most relevant. The Food Safety and Standards Authority of India (FSSAI) regulates food, including the nutraceuticals, health supplements and botanical-ingredient space through its dedicated nutraceutical regulations, which set out permitted ingredients, limits and labelling for food-grade material. Separately, the Ministry of AYUSH oversees the traditional-medicine systems (Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy); where a product is positioned as a traditional medicine rather than a food, AYUSH licensing rather than FSSAI may apply.

Export registration and phytosanitary controls

On the trade side, exporters of many agricultural and processed products work with the Agricultural and Processed Food Products Export Development Authority (APEDA) and obtain a Registration-Cum-Membership Certificate (RCMC), which evidences registration as an exporter and supports access to export schemes. Shipments of plant-derived material frequently also require a phytosanitary certificate issued under the national plant-protection authority, attesting that the consignment meets the importing country's plant-health requirements. The exact registrations and certificates depend on the product, its classification and the destination, and should be confirmed for each lane.

Other key markets, briefly

Beyond the US, EU and India, several markets have distinctive frameworks worth knowing at orientation level:

• Japan — operates a tiered system of foods with claims: the long-standing Foods for Specified Health Uses (FOSHU), which require individual approval, and the newer Foods with Function Claims, a notification-based route where the company holds the supporting evidence. Both sit within a food framework distinct from pharmaceuticals.
• Canada — regulates many botanical products as Natural Health Products (NHPs), which require a pre-market product licence (and a Natural Product Number) and licensed sites; this is a distinct, relatively structured pre-market regime compared with the US supplement model.
• Australia — the Therapeutic Goods Administration (TGA) regulates many herbal products as complementary medicines, commonly entered on the register as 'listed' medicines, which must use only pre-approved low-risk ingredients and permitted claims and meet defined quality requirements.
• China — maintains a demanding framework for health foods, historically involving registration or filing pathways and specific requirements for imported products; it generally warrants dedicated local regulatory advice given its complexity and pace of change.

Cross-cutting requirements that apply almost everywhere

Whatever the category, a set of quality and labelling expectations recurs across markets. These are where pharmacopoeias and horizontal food rules do much of the work.

Contaminant limits and pharmacopoeias

Limits for heavy metals (typically lead, arsenic, cadmium and mercury), pesticide residues and microbial counts are near-universal, even though the exact numbers and methods differ by market. Pharmacopoeias are the common reference points: the United States Pharmacopeia (USP), the European Pharmacopoeia (EP / Ph. Eur.) and the Indian Pharmacopoeia (IP) all set out test methods and acceptance criteria for herbal materials and contaminants. A specification and Certificate of Analysis should state which standard the limits are drawn from and confirm they match what the destination market enforces for the intended use and serving size.

Allergen, GMO and certification labelling

Allergen declaration rules (for carriers and processing aids as well as the active), and in many markets GMO labelling obligations, apply to botanical ingredients like any other food input. Layered on top are voluntary but commercially important certifications — organic, Kosher and Halal — each with its own audited chain-of-custody documentation that travels with the material and underpins the corresponding label claim.

The documents that travel with a shipment

Regardless of category, a consignment is expected to be accompanied by a recognisable document set. The core items are summarised below; the precise list depends on the product, the market and the buyer's quality agreement.

An export-readiness documentation checklist

Before a botanical ingredient ships, assemble and reconcile the documentation set. The order below moves from defining the product to clearing the border:

1. 1Confirm the destination-market classification — food, supplement, novel food or medicine — for the specific extract, form and intended claim, with regulatory counsel where the answer is not obvious.
2. 2Technical specification — botanical identity (Latin binomial and plant part), standardised marker and method, extraction solvent, carrier, and full acceptance limits.
3. 3Certificate of Analysis (COA) — lot-specific results against the specification, including the safety panel (heavy metals, pesticides, microbial, residual solvents) referenced to the relevant pharmacopoeia.
4. 4Safety Data Sheet (SDS) — handling, hazard and transport information for the material.
5. 5Allergen statement / declaration — covering the active, carrier and processing aids, to support destination-market labelling.
6. 6Certificate of Origin (CoO) — attesting the country of origin for customs and tariff purposes.
7. 7Phytosanitary certificate — where the plant-derived material and destination require it, issued by the competent plant-protection authority.
8. 8Certifications as applicable — organic, Kosher, Halal, GMP and lab-accreditation certificates, with numbers and scopes that verify and match the supplying entity.
9. 9Regulatory / claim dossier — substantiation for any claim, plus any market-specific notification or authorisation references (e.g. NDI notification, novel-food status, NPN, listing number).
10. 10Commercial and transport documents — invoice, packing list and any import permits, with the lot number consistent across every document so the shipment traces back to its batch record.

Putting the map to work

The practical discipline is to resolve the regulatory questions early, in parallel with formulation, rather than after it. Decide the destination market and the claim; from those, derive the category and the gatekeeper; from the category, derive the dossier, the contaminant standard and the documentation set. Build the evidence and the paperwork to the strictest market you intend to serve, and you give yourself optionality rather than a series of expensive reworks. Treat the regulatory map as part of the product brief, alongside the marker percentage and the cost target.